Advertisement

Topics

Illumina Granted FDA Approval for Next-Generation Sequencing Cancer Companion Diagnostic Test Kit

09:18 EDT 30 Jun 2017 | Speciality Pharma Journal

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced its Extended RAS Panel, an FDA-approved next-generation sequencing (NGS) kit that meets the newly published guidelines for evaluation of colorectal cancer from the American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology …

Original Article: Illumina Granted FDA Approval for Next-Generation Sequencing Cancer Companion Diagnostic Test Kit

NEXT ARTICLE

More From BioPortfolio on "Illumina Granted FDA Approval for Next-Generation Sequencing Cancer Companion Diagnostic Test Kit"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...